ATP5A Antibody (Rabbit mAb) [H6A8]

CatNo: F8999

    Application: Reactivity:
    • Lane 1: HepG2, Lane 2: HeLa, Lane 3: Mouse brain, Lane 4: Rat brain
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:1000 - 1:10000
    1:500
    1:100 - 1:250
    1:10 - 1:100
    Application
    WB, IHC, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Rat, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    60 kDa
    ポジティブコントロール Human liver tissue; Human fetal heart tissue; Rat kidney tissue; Mouse kidney tissue; Mouse brain tissue; Rat brain tissue; Human fetal liver tissue; Human fetal lung tissue; HeLa cells; MCF7 cells; HepG2 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use primary antibody dilution buffer to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    ATP5A Antibody (Rabbit mAb) [H6A8] detects endogenous levels of total ATP5A protein.
    タンパク質の局在
    細胞膜、細胞内膜系、ミトコンドリア、ミトコンドリア内膜
    Uniprot ID
    P25705
    Clone
    H6A8
    Synonym(s)
    ATP5A, ATP5A1, ATP5AL2, ATPM, ATP5F1A, ATP synthase F1 subunit alpha
    Background
    ATP5A (ATP5F1A), also known as ATP synthase F1 subunit α, is a nuclear‑encoded, mitochondrially localized subunit of complex V that forms part of the catalytic F1 head of the ATP synthase holoenzyme and is essential for oxidative phosphorylation‑driven ATP synthesis, acting both as a structural scaffold for the β catalytic subunits and as a regulatory element that coordinates nucleotide binding and release during rotary catalysis. The F1 portion of mitochondrial ATP synthase comprises three α and three β subunits arranged alternately around the central γ shaft together with δ and ε subunits, and primary structure and stoichiometry studies of bovine F1 showed that the α subunit is weakly homologous to β, resides at the noncatalytic nucleotide‑binding sites and contributes to conformational coupling between β active sites and the rotary stalk; more recent structural modeling of human ATP5F1A variants confirms that the α subunit presents a β‑interacting surface adjacent to the β catalytic site whose charge distribution and geometry are critical for complex stability and function. During oxidative phosphorylation, proton motive force generated by the electron transport chain drives rotation of the Fo c‑ring and central stalk, while the α3β3 hexamer undergoes sequential conformational changes that alternately bind ADP and inorganic phosphate, catalyze ATP formation and release product, and ATP5F1A participates by binding noncatalytic nucleotides and transmitting mechanical energy to β subunits, with defects in α–β interactions impairing rotary coupling and ATP output. Pathogenic ATP5F1A variants illustrate the functional importance of this interface: a recurrent de novo Arg207His substitution creates an abnormal region of negative charge on the β‑interacting surface of α, adjacent to the β active site, leading to complex V assembly defects, reduced ATP synthesis, neonatal hyperlactatemia and hyperammonemia, and a remitting clinical course with apparent resolution of symptoms by 18 months, while other dominant‑negative missense variants cause persistent developmental delay, neuro‑motor impairments and biochemical complex V deficiency, demonstrating that subtle changes in ATP5F1A structure can produce a spectrum of mitochondrial encephalopathies. Earlier work on a complex V ATP5A1 defect in two siblings with fatal neonatal mitochondrial encephalopathy showed that a heterozygous ATP5A1 mutation combined with silencing of the maternal allele reduced ATP5A1 expression to about half of normal, destabilized the α–β interaction, decreased complex V content and activity, and that complementation with wild‑type ATP5A1 restored complex V function in patient fibroblasts, confirming that ATP5A is indispensable for holoenzyme stability and that dosage effects can be sufficient to cause severe disease. Beyond its canonical bioenergetic role, ATP5A1 has been implicated in transcriptional and post‑transcriptional regulation in cancer cells, where aberrant expression and alternative splicing of ATP5A1 correlate with changes in oncogene regulation and tumor progression, and ATP synthase modulation by small molecules such as Mitochonic Acid 5, which facilitates ATP synthase oligomerization and improves survival in mitochondrial disease models, underscores the therapeutic relevance of targeting ATP5A‑containing complexes in disorders of energy metabolism. Recent preprint work indicates that specific cytosolic RNAs can bind ATP5A1 precursor proteins at the outer mitochondrial surface and promote their import, adding a riboregulatory layer to ATP5A biogenesis and suggesting that dysregulation of RNA‑mediated import may contribute to complex V deficiencies.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください